ONCOLOGY
At Sterling Analytics, we provide specialized statistical and analytical services to support clinical development in oncology and rare endocrine disorders. These areas require precision, adaptability, and a deep understanding of both disease biology and regulatory expectations. Our team is experienced in navigating the unique challenges of small patient populations, evolving endpoints, and high-stakes therapeutic innovation.
Whether supporting rare disease breakthroughs or leading-edge cancer treatments, Sterling Analytics is a trusted partner for transforming complex trial data into regulatory-ready evidence.
OUR AREAS OF EXPERTISE:
🟣Rare Endocrine Disorders
We offer analytical expertise for trials targeting rare and often difficult-to-diagnose conditions such as:
    🟡Acromegaly
    🟡Cushing’s Syndrome
    🟡Carcinoid Tumors
Our team supports sponsors in designing efficient studies, managing limited data sets, and ensuring rigorous statistical approaches that meet regulatory scrutiny.
🟣Liquid Tumors
We support oncology trials across a range of hematologic malignancies, including:
    🟡Acute Myeloid Leukemia (AML)
    🟡 Lymphoma
    🟡Multiple Myeloma
Our statistical strategies include adaptive designs, progression-free survival modeling, and robust safety signal detection to help bring novel therapies to patients faster.
🟣Solid Tumors
With extensive experience in solid tumor trials, we deliver full-service analytics for:
     🟡Non-Small Cell Lung Cancer (NSCLC)
     🟡Breast Cancer
     🟡Brain Cancer
     🟡Colorectal Cancer
From early-phase biomarker discovery to late-phase efficacy studies, our team ensures clean, accurate, and meaningful data interpretation to support therapeutic success.